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BALB/c mice, in contrast to most other mouse strains, are extremely susceptible
to infection with the intracellular, protozoan parasites ofthe genus Leishmania (1).
L. major, for example, multiplies progressively at the site of primary cutaneous in-
fection in the footpad, and rapidly disseminates to visceral and distinct cutaneous
sites (2). Several hypotheses have been put forward to explain the failure ofBALB/c
miceto generate a therapeuticlevel ofantiLeishmania immunity (3). Ithas been pro-
posed (4), for example, that the protective immune response in the BALB/c host
is downregulated by Leishmania-induced suppressor T (Ts) cells, via a mechanism
similarto that which down-regulates the immune responseto immunogenic murine
tumors (5). An entirely different hypothesis that has been offered is that the suscep-
tibility of BALB/c mice is caused by "disease-promoting" (6, 7) sensitized T cells
that function to recruit toomany mononuclearphagocytes tosites ofinfection, thereby
providing the parasite with host cells within which it must reside and multiply.
It needs to be realized that, in spite of their innate susceptibility, BALB/c mice
nonetheless possess the capacity to generate a protective immune response. It has
been shown that immunizing BALB/c mice with attenuated parasites (8), or with
live parasites (9) and parasite antigens (10, 11) admixed with adjuvant, renders the
mice resistant to an otherwise lethal challenge infection. The immunity generated
is T cell mediated (4), although the identity of the T cells involved has yet to be
unequivocally established. Moll et al. (12) have presented evidence that L3T4+
(CD4+) T cells alone are sufficient to reconstitute immunity in athymic BALB/c
mice. However, in contradiction to this, other investigators (13-15) have shown that
BALB/c mice rendered deficient in CD4+ T cells by treatment with anti-L3T4 mAb
paradoxically develop the capacity to resolve Leishmania infection. In an attempt to
reconcile these contradictory findings, it has been argued (12, 15) that the immunity
that develops in anti-L3T4 mAb-treated mice is mediated by residual CD4+ T cells.
The obvious alternative explanation, that immunity in anti-L3T4 mAb-treated mice
is mediated by Ly-2+ (CD8+) T cell (16), apparently has not been seriously consid-
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ered, because it would not be in keeping with the rule that CD4+ T cells are the
only cells that mediate delayed-type hypersensitivity (DTH)' (15, 17, 18).
The purpose of this paper is to present evidence that CD4+ Ts cells are respon-
sible for the susceptibility of BALB/c mice to L. major infection. It will demonstrate
that eliminating CD4+ Ts cells with a single dose of anti-L3T4 mAb releases CD8+
T cells to mediate a protective immune response capable of eliminating Leishmania
from the primary lesion, and ofpreventing the parasite from disseminating to visceral
sites.
Materials and Methods
Mice.
￿
Male BALB/c and B6.PLThy-la/Cy (C57BL/6Thy-1.1) mice, 7-10 wk old, were
obtained from the Trudeau Institute Animal Breeding Facility. The mice were reared under
barrier-sustained conditions and were shown to be free of common viral pathogens by sero-
logical testing (Charles River Technical Services, Wilmington, MA).
Parasite.
￿
Amastigotes of L. major, strain 173 (MHOM/IR/-/73) (19), were obtained from
the footpads of BALB/c mice as previously described (20). Primary subcutaneous infections
were initiated by injecting 105 amastigotes in 50 /Al of PBS into the left hind footpad. To follow
the development of disease, the size of the cutaneous lesion was determined by measuring
the thickness of the foot at regular intervals. The numbers of viable parasites in the primary
lesion (hind footpad), liver, and spleen were determined by plating appropriately diluted ali-
quots ofhomogenized tissues onto heart-infusion agar (20). After 5-7 d of incubation at 26°C,
the promastigote colonies were counted, and the number of viable parasites (CFU) present
in the tissues calculated.
In Vivo Depletion of T Cell Subsets.
￿
The hybridoma GK1.5 (Dr. Frank Fitch, University
of Chicago, Chicago, IL) secreting rat IgG2b anti-L3T4 mAb, and hybridomas 30-H12 and
TIB-210 (American Type Culture Collection, Rockville, MD) producing IgG2b antiThy-1.2
and anti-Ly-2 .2 mAb, respectively, were grown as ascites in pristane-primed, irradiated BALB/c
mice. The IgG2b content of the ascites fluid was quantified by radial immunodiffusion, and
the fluids were stored at -70°C until needed. To deplete T cell subsets in vivo, BALB/c mice
were thymectomized at 7 wk of age and infused intravenously 1 wk later with a single 1-mg
dose of the appropriate mAb, as previously described (21, 22). One group of control mice
received 1 mg of normal, affinity-purified rat IgG (ICN Immunobiologicals, Lisle, IL). The
extent ofT cell depletion was determined 1 wk later, and at 5 wk ofinfection, by flow cytofluoro-
metric analysis with a FACScan cytofluorometer (Becton Dickinson & Co., Sunnyvale, CA).
Spleen cells were stained with FITC-conjugated antiThy-1.2, anti-L3T4, and anti-Ly-2.2 mAbs
(22), and the results are expressed as the number of CD4' and CD8' T cells per spleen.
Delayed-type Hypersensitivity.
￿
The capacity of Leishmania-infected mice to express a DTH
response was examined using live amastigotes as the eliciting antigen. 72 h before a sched-
uled sacrifice, baseline measurements of footpad thickness were made, and 106 amastigotes
were implanted in the right hind footpad (contralateral to primary footpad lesion). At 3, 6,
12, 24, 36, 48, and 72 h, measurements offootpad thickness were made on individually num-
bered mice.
Results
Depletion of CD4+ T Cells Alone, or CD4+ plus CD8+ T Cells, Results in a Reduction
in the Size of the Lesion that Develops at the Site of Leishmania Inoculation. Fig. 1 shows
the effect of an intravenous infusion of mAbs specific for T cell subsets on the devel-
opment ofthe cutaneous lesion in the Leishmania-inoculated footpad of BALB/c mice.
It can be seen that an increase in the thickness of the infected footpad was first evi-
' Abbreviation used in this paper: DTH, delayed-type hypersensitivity.E
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FIGURE 1.
￿
Development of primary lesions in
the footpad ofuntreated andmAb-treated mice.
Thymectomized mice were treated with 1 mg of
anti-L3T4 (CD4) mAb, anti-Ly-2-2 (CD8) mAb,
both mAbs, or 1 mg of affinity-purified rat IgG
(treatment control). 1 wk later, these mice, along
with thymectomized untreated controls, were in-
fected in the left hind footpad with 105 L. major
amastigotes. Lesion size is the difference between
the thickness of the inoculated foot and that of
the contralateral uninfected foot. Data are ex-
pressed as the mean of four to six mice per time
point. The SD were always 420% of the mean.
dent at 3 wk of infection in all experimental groups. In the control mice, and in
mice treated with anti-Ly-2 mAb, footpad size continued to increase until 8 wk of
infection, afterwhich theentire foot became necrotic, and no furthermeasurements
were possible. In contrast, treatment with either anti-L3T4 mAb alone, or anti-L3T4
plus anti-Ly-2 mAb, prevented the lesion from increasing in"size,~after 5 wk. This
result would generally be taken to mean that the infection hadlailled to progress
in these last mentioned mice.
That treatment with mAb as described above depleted mice of the appropriate
T cell subsets is evidenced by the results of flow cytofluorometric analysis of spleen
cells shown in Table I. It can be seen that at 5 wk of infection, the absolute numbers
of CD4+ and CD8+ T cells in mAb-treated mice were <90% of normal. Residual
TABLE I
Numbers of CD4+ and CD8+ Spleen Cells Present in mAb-treated
BALBlc Mice at 5 wk of Leishmania major Infection
BALB/c mice were thymectomized at 7 wk of age and treated 1 wk later with
1 mg of the appropriate mAb. Groups of mice were infected 1 wk after treat-
ment, and their pooled spleens were analyzed 5 wk later. Absolute numbers were
calculated from the percentages obtained from flow cytofluorometric analysis of
spleen cells stained with FITC-conjugated anti-Thjy-1 .2, anti=L3T4 (CD4), and
anti-Ly-2 (CD8) mAb. The numbers have not been corrected for background.
Therefore, they represent the maximum number present in the organ. Theback-
ground staining with anti-Thy-1 .2 on spleen cells from B6.Thy-1.1 mice was 2% .
Treatment Total Thy-1 .2' CD4* CD8*
x 10-6
Untreated control 140 21 .8 20.0 8.1
Rat IgG control 190 27 .8 14.3 10.5
Anti-L3T4 mAb 260 13.5 <1 .8 8.0
Anti-Ly-2 mAb 250 23.2 22.0 <2.0
Anti-L3T4 mAb +
Anti-Ly-2 mAb 40 <0.4 <0.3 <0.2
Untreated C57BL/6-Thy-1 .1
(negative control) 160 3.2 ND ND1822
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TABLE II
Number (Logio) of Viable Parasites in T cell-depleted BALBIc Mice at 5 and 10 wk
of Leishmania major Infection
Thymectomized BALB/c mice were treated with 1 mg ofappropriate mAb(s) and infected in the hind foot-
pad with 105 L. major amastigotes 1 wk later. Data are expressed as the mean ± SD of four to six mice.
At 10 wk the entire foot of mice in these groups had become necrotic and had been lost.
1 No viable parasites could be detected in these mice. The detection limit for viable parasites in this study
was 200 (2.30 logs).
4 Mice in this group had died of systemic disease by 10 wk.
stainingwas below the background seen inC57BL/6Thy-1.1 spleen cellsstained with
FITC-conjugated antiThy-1.2 mAb. It is possible, therefore, that the targeted T cell
subset had been completely eliminated by mAb treatment.
Only Mice Depleted of CD4+ T Cells Alone Were Capable of Destroying Parasites in the
Primary Lesion and in Visceral Metastatic Foci. The foregoing results suggest that if
lesion size is taken as an indicator ofdisease status, mice depleted ofCD4+ Tcells
alone, or of both CD4+ and CD8+ T cells, are resistant to cutaneous L. major in-
fection. Indeed, enumeration ofthe parasite in the footpads and livers (Table II)
revealed that mice depleted ofCD4+ T cells were able to prevent the parasite from
multiplying progressively at the primary site ofinfection. At 5 wk, the footpad of
anti-L3T4 mAb-treated mice had <1% of the number of parasites found in the
footpad of untreated control mice. In fact, by 10 wk, the parasites had been com-
pletelyeliminated from the primary lesion, and the small number ofLeishmaniathat
had disseminated to the liver had been destroyed.
However, the situation in mice treated with anti-L3T4 plus anti-Ly-2 mAbs was
entirely different. In spite of the fact that the primary lesions of mice depleted of
both subsets ofT cells were small, these mice proved to have progressive disease. At
5 wk of infection their cutaneous lesions contained up to 10$ viable parasites, and
by the ninth week, they began to die of systemic disease. These results show, there-
fore, that treatment with anti-Ly-2 mAb completely negated the therapeutic effect
oftreatment with anti-L3T4 mAb. It follows, therefore, that CD8+ T cells are es-
sential for a successful protective immuneresponse againstLeuhmanta in BALB/cmice.
BALB/c Mice Depleted Only of CD4' T Cells Acquire a Sustained Capacity to Express a
Cutaneous DTH Response to Leishmania Antigens. At 5 and 10 wk of the Leishmania
infection, control and mAb-treated mice were tested for their capacity to express
a DTH response to Letshmania amastigotes implanted in the foot contralateral to
thatcontaining theprimary lesion. The criterionfor a positive DTHwasanincrease
Treatment Primary
5
lesion
Weeks
Liver
of infection
10
Primary lesion Liver
toglo
Untreated control 8.01 t 0 .31 4.54 ± 0 .78 -' 6.85 ± 0.71
Rat IgG control 7.46 t 0 .32 3.93 t 0 .44 -* 6.76 t 0.71
Anti-L3T4 mAb 5.35 t 0 .57 2.65 ± 0 .38 <2.301 <2.301
Anti-Ly-2 mAb 7.52 t 0 .35 4.23 ± 0 .27 -" 6.54 t 0.81
Anti-L3T4 mAb +
anti-Ly-2 mAb 7 .54 t 0.40 4.15 f 0.78 -$ -4z
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TABLE III
Magnitude of the DTH Response Elicited by an Intrafootpad Injection of
Leishmania major Amastigotes in BALBIc Mice
Depleted of CD4+ or CD8+ T Cells
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FIGURE 2.
￿
Kinetics of DTH response elicited at 5 wk
ofL. major infection in BALB/c mice depleted ofL3T4'
(CD4') T cells, Ly-2' (CD8') T cells, or both T cell
subpopulations. Thymectomized mice were treatedwith
1 mg of anti-L3T4 mAb, anti-Ly-2 mAb, both mAbs,
or 1 mg ofaffinity-purified rat IgG(treatment control).
1 wk later, these mice, along with thymectomized un-
treated controls were infected in the left hind footpad
with 105L. majoramastigotes. To elicit DTH, aftertak-
ingbaseline measurements oftherighthind footpad (con-
tralateral to primarylesion) offour to sixmice from each
treatment group, 106 amastigotes were implanted in
that site. Dataareexpressedas footpad swelling (0.1 mm),
i.e., the increase in the thicknessofthe inoculated foot
at the stated times after challenge.
ThymectomizedBALB/c mice were treated with 1 mg ofappropriate mAb(s)
andinfected in the hind footpad with 105 L. majoramastigotes 1 wk later. Data
areexpressed as the mean ( t SD)increase in thickness(0 .1 mm) ofthe foot-
pads of four to six mice at 24 h after injection of 106 L. major amastigotes.
' Mice in this group had died of systemic disease by 10 wk.
in footpad swelling, which reached a maximum at 24 h, and declined to baseline
by 72 h. The time courses ofthe DTH responses are shown in Fig. 2, where it can
be seen that all mice, except those depleted ofboth CD4+ and CD8+ T cells, were
capable ofexpressing a delayed inflammatory response at 5 wk ofinfection. Impor-
tantly, the largest response was expressed by CD4+ Tcell-depleted mice. Further-
more, CD4+ T cell-depleted mice were capable ofexpressing DTH at 10 wk ofin-
fection (Table III), whereas thecapacityoftheothergroups to expressaDTH response
had waned. These results therefore show that eliminating CD4+ T cells not only
allows CD8+ Tcells to mediate protective immunity, but that acquisition ofCD8+
T cell-mediated protective immunity correlates with the sustained capacity ofthe
mice to express a DTH response to amastigote antigens.
Discussion
Thispaperconfirms the resultsofothers (13) byshowingthattreatmentofLeishmania-
susceptibleBALB/c mice with anti-L3T4mAb convertsthem toresistantmice capable
of eliminating Leishmania from the site of primary infection and of preventing the
Treatment
Week
5
of infection
10
Untreated control 5.2 t 2.8 4.0 t 2.1
Anti-L3T4 mAb 11 .2 t 1.5 16.8 f 3.2
Anti-Ly-2 mAb 8.2 t 3.4 4.5 t 1.3
Anti-L3T4 mAb + anti-Ly-2 mAb 3.0 t 1.6 -"
Uninfected, untreated controls 3.2 t 1.2 4.3 t 0.61824
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disseminationoftheparasite to theviscera. This effect ofanti-L3T4mAbtreatment
is somewhat paradoxical, considering the generally held view that CD4+ T cells are
responsiblefor mediating antiLeishmaniaimmunity byway oftheirabilityto activate
the antimicrobial capacity ofmacrophages viathe secretion oflymphokines (4). In-
deed, in order to conform to this view,some (12, 15) have attempted to explain the
therapeuticeffect ofanti-L3T4mAb treatmentby suggestingthatimmunity ismedi-
ated by CD4+ T cells that survive mAb treatment. However, the recent results of
Tituset al. (16)challenge the beliefthat antiLeishmania immunity resides exclusively
within the CD4+ T cell subpopulation. These workers found that anti-Ly-2 mAb
treatment can exacerbate disease in susceptible BALB/c mice, and also delay, to a
certain extent, healing oflesions in the genetically resistant CBA host. The results
presented here clearly show that the CD8+ T cell subset is essential for antiLeish-
mania immunity. They show that the parasite multiplies progressively in anti-Ly-2
mAb-treatedmice, andin mice treated with anti-Ly-2 plusanti-L3T4 mAb. Incon-
trast, mice treated with the anti-L3T4 mAb alone acquired the ability to control
Leishmania multiplication and to eliminate the parasite in <10 wk. Therefore, there
can be little doubt that CD8+ Tcells are key protective cells, and that CD8+ T cells
can perform their protective role in the virtual absence of the CD4+ T cell subset.
This central role for CD8+ T cells in immunity is in agreement with the interpre-
tation ofapublished (23)immunohistochemical study ofLeishmania-induced granu-
lomas in the livers ofBALB/c mice. This published study shows that CD8+ T cells
predominate at a time when the parasite is being eliminated from foci ofinfection.
As to the reason why CD4+ T cells need to be eliminated in order for CD8+ T
cells to perform their protective function, the results presented do not support the
view that BALB/c mice normally generate too many Leishmania-sensitized CD4+ T
cellsand, consequently, express disease-promotinglevels ofDTH (6, 7). The notion
that DTH-mediated accumulation oftoo many mononuclearphagocytes at the site
ofinfection provides Leishmania with cells for it to enter and multiply in is difficult
to reconcile with the evidence that mononuclear phagocytes are the cells that are
eventually responsible for destroying the parasite. The results presented here indi-
cate that DTH, per se, is not a disease-promoting mechanism. On the one hand,
susceptible BALB/c mice not depleted ofCD4+ T cells actually had a reduced ca-
pacity to express DTH. On the other hand, depletion ofCD4+ T cells allowed mice
to generate higher levels ofDTH. Moreover, the acquisition ofDTH was associated
with the generation of an immune response that prevented rather than promoted
the multiplication of the parasite.
Akeyfinding from this study is that both DTH and protective immunity to Leish-
mania are mediated by CD8+ T cells. Both mechanisms were expressed in the vir-
tual absence ofCD4+ Tcells, but not in the absence ofCD8+ T cells. Even so, these
results do not rule out a possible role for CD4+ T cells in the DTH response to Leish-
mania. Indeed, mice treated with the anti-Ly-2 mAb alone also acquired a short-
lived capacity to mount a response to an intrafootpad injection ofLeishmania amasti-
gotes. Ithasbeen suggested, however, that this inflammatory reaction in susceptible
BALB/c mice may not be a true DTH reaction (24). Until this possibility is inves-
tigated, the results can be interpreted to mean that CD8+ as well as CD4+ T cells
can mediate DTH in Leishmania-infected BALB/c mice.HILL ET AL.
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Given what is currently known about the response ofBALB/c mice to Leishmania
infection, themost plausibleexplanation for the impressive therapeuticeffect ofanti-
L3T4 mAb treatment is that the mAb eliminates CD4' Ts cells, thereby releasing
Leishmania-sensitized CD8' T cells to mediate protective immunity. It is apparent
that there has been a reluctance to invoke Ts cells to explain the effect ofanti-L3T4
mAbtreatment, in spite ofthe fact that there are several publications (25-27) showing
that Leishmania-infected mice generate CD4' T cells capable, on passive transfer,
ofsuppressingantiLeishmania immunity in BALB/c mice. It should be pointed out,
moreover, that CD4' T cells have been shown to mediate unresponsiveness to a
number ofantigens (28-31). In this regard, the results presented here are strikingly
similar to those recently obtained from a study ofthe effect ofdeleting T cell subsets
on the growth of an immunogenic tumor. It was shown (22) that deleting CD4'
T cells resulted in complete regression ofthe tumor and in long-term host survival.
In contrast, deleting CD8' T cells resulted in enhanced tumor growth and in
shorter host survival time.
The last finding deservingofdiscussion is that the size ofthe primary lesion need
not be a reflection ofthe parasite load in the primary lesion, nor of the severity of
systemic disease. On the contrary, the results show that the largestnumbers ofLeish-
mania were present in some ofthe smallest lesions, namely, in the footpads of mice
depleted ofboth T cell subsets. Thus, the increased thickness ofan infected footpad
does not represent the space occupied by parasites. Rather, it probably represents
mostly edema caused by the host's inflammatory response. It is possible, therefore,
that much ofthe past confusion about both the nature ofunderlying antiLeishmania
immunity in the susceptible host, and the mechanism that suppresses it, has been
caused by too heavy a reliance on lesion size measurements to monitor the progress
of infection. The current studies serve to emphasize that the only acceptable way
to determine the disease status ofthe host at any one time is to enumerate the para-
sites in the primary lesion and elsewhere.
Summary
This study examined the capacity of BALB/c mice that had been depleted of T
cell subpopulations to generate a protective immune response to Leishmania major.
Thymectomized mice were depleted ofeither L3T4' (CD4') T lymphocytes, Ly-
2' (CD8') T lymphocytes, or both, by treatment with appropriate mAbs. It was
found that susceptible mice were rendered resistant to Leishmania by an intravenous
infusion of anti-L3T4 mAb. These mice generated an immune response that de-
stroyed the parasite in the primary lesion and in visceral metastatic foci. CD4'
cell-depleted mice also acquired a capacity tomount asustained delayed-type hyper-
sensitivity (DTH) response to parasite antigens, indicating that DTH, per se, is not
adisease-promoting mechanism in the susceptible murine host ashas been suggested.
Depleting BALB/c mice ofCD8', as well as CD4' T cells, left them highly suscep-
tible to Leishmania infection, thereby indicating that CD8' lymphocytes are key pro-
tectivecells. Ourresults canbe interpreted as showingthat the susceptibility ofBALB/c
mice is due to the generation of CD4' cells that suppress either the generation or
expression of CD8' T cell-mediated antiLeishmania immunity.1826
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